Several works have shown the potential of C. asiatica to be used against neuropathologies, such as in neurodegeneration [58] and neuroimmune diseases [59]. A systematic review with meta-analysis showed that C. asiatica can improve alertness and relieve anger, symptoms associated with mood outcomes [60], findings which reinforces the pharmacological application of this plant. Furthermore, a phase 1 clinical study indicated that doses around 250 mg to 500 mg of standardized extract from C. asiatica had no collateral effects and was well tolerated in healthy humans [61]. Thus, grounded in these previous robust scientific reports, we evaluated the effect of HECa and madecassic acid in rats submitted to the early-life MD protocol. In an unprecedented manner, we found that HECa and madecassic acid reversed or significantly reduced depressive-like behaviors, inflammation in the hippocampus, and oxidative stress in the serum and hippocampus.
In the first experiment, we induced depressive-like behaviors in rats through MD protocol as described in other studies [27, 62]. The forced swimming test was used to assess depressive-like behaviors. This test is widely used to evaluate the effects of substances with antidepressant potential [63–65]. As predicted, early life MD protocol culminated in depressive-like behaviors in adulthood animals, corroborating the scientific literature reported [62, 66–69].
In parallel, early-life MD groups were treated with HECa (30 mg/kg), madecassic acid (10 mg/kg), and escitalopram (10 mg/kg) to assess its potential for reversion of depressive-like behavior. All treatments were capable of reducing stress-induced depressive-like behaviors. In this context, Sun et al. [70] evidenced that both madecassic acid and asiatic acid (from C. asiatica) decreased the immobility time in the forced swim test. Likewise, Kalshetty et al. [40] proved that extract of C. asiatica exhibited antidepressant-like effects in a protocol of olfactory bulbectomy in rats. The effect of escitalopram was according to literature since this drug is well-known as a classic antidepressant involved in reducing clinical depression symptoms and depressive-like behaviors in animal models [71–74]. Similar results of improvement in depressive-like behavior were found from the chronic administration of catechin, one of the compounds identified in the analysis of the plant extract, in a model of depression also in rats [75]. It is essential to highlight that this is the first study that observed the antidepressant-like effect of this medicinal species using the MD protocol and the forced swimming test.
The alterations in the parameters of the forced swimming test indicate that the treatment with HECa and madecassic acid contribute positively to reducing depressive-like behaviors caused by MD in rodents, a response possibly mediated by the neuroprotective effect of the administered herbal substances.
MD and pharmacological treatments did not induce changes in open-field mobility parameters. The locomotor activity evaluated in this test is a parameter from the sedative or stimulant effect from stress or treatments [76], so this result indicates that the stress protocol or drugs did not induce a significant sedative or stimulant effect that could interfere with the animals' mobility behaviors.
The reduction in immobility time evaluated in the forced swimming test, induced by HECa and madecassic acid, suggests that this plant and its active compound have a potential antidepressant effect. Research suggests that increased swimming time and decreased immobility time in the forced swimming test are related to the activation of the serotonergic system and the increased time of serotonin in the synaptic cleft. Treatment with classic antidepressants that cause serotonergic modulation reduces immobility time and increases swimming time [77–79].
Although the literature does not have results with protocols similar to this work, a recent study observed that verbascoside (asiaticoside) pointed in this study, and a triterpenoid component of C. asiatica, exerted an antidepressant-like effect in mice subjected to chronic moderate stress and reduced the expression of inflammatory cytokines [37].
A recent study provides evidence of the antioxidant, anti-aging, and anti-stress effects of a regular diet containing a composition of C. asiatica with vitamins C and D and zinc in an animal model with middle-aged rats [80]. Besides, the medicinal species was considered in this research because it has a neuroprotective potential [58]. In vitro research found that the active compound madecassic acid has a strong effect on potentiating telomerase activity [80]. The telomerase enzyme is crucial in preventing telomere shortening and, consequently, inflammation, aging, and cell death, which are also involved in the pathophysiology of MDD [36, 81, 82]. The chronic stress experienced by individuals with MDD culminates in chronic systemic inflammation and, concomitantly, reduces telomerase activity and induces cellular aging [83].
Immune alterations, such as increased levels of IL-1β and IL-6, contribute to the pathophysiology of MDD [84]. Other studies have shown changes in inflammatory mediators in animals that have experienced stressors, such as MD and adulthood chronic stress, and have shown depressive-like behavior in behavioral tests [45, 85]. Hippocampus is a brain region potentially affected by neuroinflammation and is related to memory, learning, and negative feedback regulation to the HPA axis, which interacts and interferes with immune system functions [62, 86, 87]. In this study, we observed that MD significantly increased IL-1β levels in the hippocampus, and the treatments with madecassic acid and escitalopram reversed the effect of MD. Similarly, MD significantly elevated IL-6 levels in the hippocampus, and treatments with HECa, madecassic acid and escitalopram reversed the effect of MD. In this study, the effects of escitalopram are in agreement with the scientific literature, considering that treatment with escitalopram in animal models of depression reverses the depressive-like symptoms induced by the model and reduces the levels of pro-inflammatory cytokines, such as IL-1β, IL-6, TNFα, and INF-γ [33].
The reduction of IL-1β and IL-6 levels in the hippocampus suggests that madecassic acid has anti-inflammatory properties and corroborates the scientific literature. An in vitro study found that madecassic acid has anti-inflammatory potential in RAW 264.7 macrophage cells, culminating in the reduction of inducible nitric oxide synthase (iNOS), COX-2, TNF-α, IL-1β, and IL-6 mRNA expression [88]. In addition, research carried out in diabetic mice showed that the administration of madecassic acid chronically caused a reduction in the levels of IL-1β and IL-6 in the kidneys and hearts of the animals [89]. In diabetic rats, chronic treatment with C. asiatica decreased renal levels of MDA, TNF-α, and interferon-γ (IFN-γ) in the kidneys and brain, reinforcing the inflammatory effect of the species [90].
Verbascoside, one of the compounds found by staying present in the HECa from this study, has been described as a potent reducer of pro-inflammatory cytokine in neuropathologies, mainly by the suppression of IL-1β and IL-6 [91]. Another compound from HECa in this research that may explain the anti-inflammatory effect is chicoric acid. It has been related to preventing neurodegeneration in the striatum of mice by regulation of IL-17, IFN-γ, and transforming growth factor beta (TGF-β), as well as mitigating dopaminergic neuronal lesions [91]. All these results corroborate the anti-inflammatory effect of HECa against neurodegeneration, as occurs in depressive-like disease.
Anti-inflammatory therapies are being widely researched for treating MDD and other psychiatric pathologies [92], and non-pharmacological treatments are therapeutic strategies to control depression. An example is regular physical exercise, which causes a response comparable to conventional therapies, individually or as an adjuvant to pharmacological therapy. Physical activities control depressive symptoms by increasing anti-inflammatory factors and processes and decreasing circulating proinflammatory substances, controlling the neuroinflammation present in the pathophysiology of MDD [87]. These results highlight the importance of expanding investigations into the potential antidepressant effects, at least partly from the anti-inflammatory properties of Centella asiatica.
The pathophysiology of MDD is closely related to oxidative stress. Furthermore, oxidative stress is closely related to neuroinflammation [93]. High levels of protein carbonylation and nitric oxide, as well as reduced SOD and glutathione, were observed in elderly individuals with MDD [94]. Interestly, chronic treatment with C. asiatica induced free radical reduction/triggered lipid peroxidation, maintained an adequate level of antioxidant enzymes in hippocampus, in animals chronically exposed to aluminum chloride (AlCl3) [95]. Given these statements, we finally evaluated the redox profile of rats after and before of treatments with HECa, madecassic acid and escitalopram. Animals that underwent MD had an increase in seric MPO levels, and increase in seric and hippocampal TBARS levels, showing that MD favors pro-oxidant conditions. Treatments with HECa, madecassic acid and escitalopram reversed these alterations. In the hippocampus, TBARS in serum and hippocampus, treatments with escitalopram and madecassic acid reversed the change (Fig. 8).
Studies indicate that the antioxidant effects of plants may be related to their anti-inflammatory effect, and in this research, C. asiatica demonstrated an anti-inflammatory effect on IL-1 and IL-6. The scientific literature points to evidence that oxidative stress is positively associated with neuroinflammation and C. asiatica is therapeutic potential in these situations [90, 96]. In vitro and in vivo analyses indicate that the plant's triterpenes contribute to the antioxidant, cholinesterase inhibitory activity, and antiamnesic effect of C. asiatica. Still, they are not the only substances with this effect in the extract [96]. Considering research on bioavailability, distribution, and antioxidative effects, it is possible to hypothesize that the C. asiatica extract did not reverse the increase in TBARS because it did not have sufficient amounts of the active compound madecassic acid, which had beneficial effects on MDA levels [97]. Still, catechin, a substance in the extract of C. asiatica used in this study, has an antioxidant potential identified in a study with obese adults. This substance was related to reducing glutathione peroxidase (GPX) levels, an essential reduction in oxidative stress in the body [98]. Another substance in the extract is ellagic acid, which reduces oxidative stress in women with polycystic ovaries [99]. In this study, there was less catechin and ellagic acid than needed for the antioxidative effect. Therefore, these results indicate that the active compound madecassic acid has potential antioxidant action to abrogate the oxidative stress.
As we found that MD protocol also induced, associated with depressive-like behaviors and inflammation, a pro-oxidant state, we searched for signals of antioxidant biomarkers. In this sense, some important antioxidant molecules involved in redox balance are those belongs to the thiols system, which is characterized by the organic sulfur derivatives known as sulfhydryl groups (-SH), such as glutathione (GSH) [100]. In this study, MD impacted in seric PSH levels with significant increase. On the other hand, the treatment with madecassic acid was capable of decreasing levels of PSH while other treatments had no effects in this biomarker (Fig. 9). It is well-known that sulfhydryl groups act as scavengers of molecules [101]. Thus, a possible explanation for increase in PSH levels is that under stress-induced by MD, this endogenous antioxidants defense increase in a homeostatic attempt to abrogate the levels of pro-oxidants molecules. In the case of treatments, the madecassic acid itself played the antioxidant role, with a reduction in PSH close to the control baselines levels in this group.
In addition, we also found increased levels of NPSH in treatment with escitalopram in the hippocampus (Fig. 9). This result is supported by several works, as shown that escitalopram suppressed the effects of increased oxidative stress, with decreasing in MDA levels in the hippocampus and increasing GSH both in the hippocampus and prefrontal cortex, as well ass alleviated stress-induced depressive and anxious behaviors in rats [102]. A study performed by Cimen et al. [103], in which subchronic treatment of patients with escitalopram modulates both oxidants and antioxidants elements leading to close health individuals.
The behavioral results, inflammatory and redox biomarkers that we observed in the this study, as well as the results in the scientific literature on the biological actions of the species C. asiatica and its active compound, madecassic acid, highlight the importance of continuity in the analysis of the anti-inflammatory, antioxidant and antidepressant profile.